Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

被引：0
作者：
Bennouna, J. [1 ]
Hiret, S. [2 ]
Borg, C. [3 ]
Bertaut, A. [4 ]
Bouche, O. [5 ]
Deplanque, G. [6 ]
Francois, E. [7 ]
Conroy, T. [8 ]
Ghiringhelli, F. [9 ]
des Guetz, G. [10 ]
Seitz, J-F. [11 ]
Artru, P. [12 ]
Stanbury, T. [13 ]
Charpentier, S. [14 ]
Denis, M. [14 ]
Adenis, A. [15 ]
机构：
[1] CHU Nantes, IMAD Digest Oncol, Nantes, France
[2] Inst Cancerol Ouest, Med Oncol, St Herblain, France
[3] CHU Besancon, Med Oncol, Besancon, France
[4] Georges Francois Leclerc Canc Ctr, Biostat, Dijon, France
[5] CHU Reims, Gastroenterol, Reims, France
[6] Hop Riviera Chablais, Med Oncol, Vevey, Switzerland
[7] Ctr Antoine Lacassagne, Med Oncol, Nice, France
[8] Inst Cancerol Lorraine, Med Oncol, Vandoeuvre Les Nancy, France
[9] Georges Francois Leclerc Canc Ctr, Med Oncol, Dijon, France
[10] CHU St Denis, Med Oncol, Limoges, France
[11] APHM, Gastroenterol, Marseille, France
[12] Hop Prive Jean Mermoz, Gastroenterol, Lyon, France
[13] UNICANCER, Invest Ctr, Paris, France
[14] CHU Nantes, Mol Biol, Nantes, France
[15] Ctr Oscar Lambret, Med Oncol, Lille, France
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
477O
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases
    Chun, You Jin
    Kim, Seong-Geun
    Lee, Keun-Wook
    Cho, Sang Hee
    Kim, Tae Won
    Baek, Ji Yeon
    Park, Young Suk
    Hong, Soojung
    Chu, Chong Woo
    Beom, Seung-Hoon
    Jung, Minkyu
    Shin, Sang Joon
    Ahn, Joong Bae
    CLINICAL COLORECTAL CANCER, 2020, 19 (03) : E140 - E150
  • [32] RANDOMISED PHASE III STUDY OF BEVACIZUMAB plus CHEMOTHERAPY BEYOND PROGRESSION IN BEVACIZUMAB-TREATED PATIENTS WITH METASTATIC COLORECTAL CANCER: TML STUDY KRAS SUBGROUP FINDINGS
    Van Cutsem, Eric
    Maria Vieitez, Jose
    Bouche, Olivier
    Osterlund, Pia
    Bennouna, Jaafar
    Andre, Thierry
    Sastre, Javier
    Alonso-Orduna, Vicente
    Kubicka, Stefan
    Greil, Richard
    von Moos, Roger
    Reyes-Rivera, Irmarie
    Scherer, Stefan
    Bendahmane, Belguendouz
    Arnold, Dirk
    ANNALS OF ONCOLOGY, 2012, 23 : 15 - 15
  • [33] CANADIAN ECONOMIC ANALYSIS OF BEVACIZUMAB, CETUXIMAB, AND PANITUMUMAB IN THE FIRST LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)
    Lawrence, D.
    Maschio, M.
    Yunger, S.
    Easaw, J.
    Aucoin, N.
    Weinstein, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 202 - 202
  • [34] SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC)
    Cohn, Allen Lee
    Hecht, J. Randolph
    Dakhil, Shaker
    Saleh, Mansoor N.
    Piperdi, Bilal
    Cline-Burkhardt, Vivian Jean M.
    Tian, Ying
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] EFFICACY OF CHEMOTHERAPY plus CETUXIMAB ACCORDING TO METASTATIC SITE IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER: ANALYSIS OF CRYSTAL AND OPUS STUDIES
    Koehne, Claus-Henning
    Bokemeyer, Carsten
    Heeger, Steffen
    Rougier, Philippe
    Van Cutsem, Eric
    ANNALS OF ONCOLOGY, 2011, 22 : v10 - v10
  • [36] A phase Ib study of AUY922 and cetuximab in patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
    Subramaniam, Somasundaram
    Goodman, Gary E.
    Boatman, Barry
    Smith, Andrew W.
    Iriarte, Desiree
    Gold, Philip Jordan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Efficacy and safety of bevacizumab (BEV) plus chemotherapy in Chinese patients (pts) with metastatic colorectal cancer (mCRC): Results from the ARTIST study.
    Guan, Z.
    Xu, J.
    Luo, R.
    Feng, F.
    Wang, L.
    Shen, L.
    Yu, S.
    Ba, Y.
    Liang, J.
    Wang, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
    Shitara, Kohei
    Yokota, Tomoya
    Takahari, Daisuke
    Shibata, Takashi
    Ura, Takashi
    Utsunomiya, Setsuo
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Najima, Mina
    Kawai, Hiroki
    Tajika, Masahiro
    Sawaki, Akira
    Yatabe, Yasushi
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (04) : 688 - 693
  • [39] Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
    Kohei Shitara
    Tomoya Yokota
    Daisuke Takahari
    Takashi Shibata
    Takashi Ura
    Setsuo Utsunomiya
    Yoshitaka Inaba
    Hidekazu Yamaura
    Yozo Sato
    Mina Najima
    Hiroki Kawai
    Masahiro Tajika
    Akira Sawaki
    Yasushi Yatabe
    Kei Muro
    Investigational New Drugs, 2011, 29 : 688 - 693
  • [40] SOX plus bevacizumab versus SOX plus cetuximab as initial treatment of recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study): A phase II randomized study.
    Okamura, Shu
    Nishizawa, Yujiro
    Kagawa, Yoshinori
    Imasato, Mitsunobu
    Miyake, Masakazu
    Ohara, Nobuyoshi
    Ide, Yoshihito
    Nonaka, Ryoji
    Tamai, Koki
    Konishi, Ken
    Kato, Takeshi
    Sawada, Genta
    Tei, Mitsuyoshi
    Satoh, Taroh
    Miyoshi, Norikatsu
    Uemura, Mamoru
    Takahashi, Hidekazu
    Murata, Kohei
    Doki, Yuichiro
    Eguchi, Hidetoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 136 - 136
12345